Trial Profile

A Prospective, National, Multi-center, Observational Real-world Study of Acalabrutinib in Chinese MCL/CLL Patients (RESA)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary)
Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms RESA

Most Recent Events

14 Sep 2026 Last checked against ClinicalTrials.gov record.
08 Sep 2026 The protocol has been amended to change in time frame.
08 Sep 2026 Planned number of patients changed from 200 to 160.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com